Veracyte, Inc. (VCYT) Stock Price
VCYTStock
$43.12+20.41%52W
Market Cap$3.47B
P/E52.24x
PEG Ratio—
Div yield—
Beta2.00
VCYT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)15.81%
Price vs S&P 500 (4W)5.18%
VGM Score52.88
P/E Ratio (Annual)52.24x
VCYT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.43 | $0.54 | +25.05%(+$0.11) | |
| Q1 2026 | $0.33 | $0.52 | +56.02%(+$0.19) | |
| Q4 2025 | $0.41 | $0.53 | +29.79%(+$0.12) | |
| Q3 2025 | $0.32 | $0.51 | +59.52%(+$0.19) | |
| Q2 2025 | $0.30 | $0.44 | +48.46%(+$0.14) |
VCYT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.22
4.22
4.21
4.21
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
| CELCCelcuity Inc. Common Stock | — | — | D | — | — | — | -244.6% | $56.58 |
About Veracyte, Inc.
Veracyte is a genomic diagnostics company providing molecular tests to help clinicians diagnose and treat cancer across multiple tumor types. Its portfolio includes Decipher tests for prostate and bladder cancer, Afirma for thyroid cancer, and Prosigna for breast cancer. These precision diagnostics enable informed clinical decision-making and improve patient outcomes at critical treatment junctures.